glp 1 liver Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH Adipose Tissue Plasticity, Lipoprotein Metabolism,

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

[13] GLP-1 medication use by age in the UK The median age of Mounjaro users in the UK is 44 years old, with those aged between 40 and 59 making up more than half of all users (53.5%)

Liraglutide and the Risk of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes: Nissen, S

FDA approvals now encompass chronic kidney disease indications for some agents, obstructive sleep apnea treatment and metabolic dysfunction associated steatotic liver disease for select products